Valion Bio (ex-Tivic Health) closes $250K post-IPO convertible financing
What's the deal? Valion Bio (VBIO), formerly known as Tivic Health Systems, has closed a $250,000 post-IPO convertible financing round. The company issued 250 shares of Series B Non-Voting Convertible Preferred Stock at $1,000 per share to investor 3i, LP, along with a warrant to purchase 156,026 shares of common stock at $0.616280 per share.
The transaction, executed on June 17, 2026, stems from a Securities Purchase Agreement originally signed in April 2025 with a different investor for up to $8.4 million. That agreement was assigned to 3i, LP in December 2025 and has since been amended multiple times.
Why now? Valion Bio operates in the biotech sector and relies on staged equity financing to fund its operations. With a market cap of just $1.79 million, the company has limited options for raising capital and appears to be drawing down funds in small increments under its existing purchase agreement rather than pursuing larger fundraises.
What could go wrong? The company's financial picture is concerning. Valion Bio faces shrinking revenue, persistent losses, negative cash flow, and what analysts describe as "significant balance-sheet erosion." The technical sentiment on the stock is bearish, with longer-term downtrends pressuring the share price.
The $250,000 raise is tiny — even by micro-cap standards — and the convertible structure could dilute existing shareholders when preferred shares convert to common stock. The fact that the original purchase agreement has changed hands and been repeatedly amended adds another layer of complexity.
The signal: 3i, LP is a well-known structured-finance investor that frequently provides capital to micro- and nano-cap public companies through convertible instruments — a niche sometimes called "toxic financing" because of its dilutive mechanics. The fact that the original $8.4 million purchase agreement changed hands and has been amended multiple times before yielding just $250,000 in proceeds suggests Valion Bio's ability to draw on the facility is tightly constrained, likely by its rock-bottom market cap and thin trading volume.
Read more: blog.tipranks.com
